- Home
- FLC vs RCEL Comparison
FLC vs RCEL Comparison
Compare FLC & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- RCEL
- Stock Information
- Founded
- FLC 2003
- RCEL N/A
- Country
- FLC United States
- RCEL United States
- Employees
- FLC N/A
- RCEL N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- RCEL Medical/Dental Instruments
- Sector
- FLC Finance
- RCEL Health Care
- Exchange
- FLC Nasdaq
- RCEL Nasdaq
- Market Cap
- FLC 174.2M
- RCEL 152.1M
- IPO Year
- FLC N/A
- RCEL N/A
- Fundamental
- Price
- FLC $17.45
- RCEL $4.21
- Analyst Decision
- FLC
- RCEL Strong Buy
- Analyst Count
- FLC 0
- RCEL 4
- Target Price
- FLC N/A
- RCEL $13.75
- AVG Volume (30 Days)
- FLC 37.8K
- RCEL 369.8K
- Earning Date
- FLC 01-01-0001
- RCEL 11-06-2025
- Dividend Yield
- FLC 6.64%
- RCEL N/A
- EPS Growth
- FLC N/A
- RCEL N/A
- EPS
- FLC N/A
- RCEL N/A
- Revenue
- FLC N/A
- RCEL $74,884,000.00
- Revenue This Year
- FLC N/A
- RCEL $28.23
- Revenue Next Year
- FLC N/A
- RCEL $35.24
- P/E Ratio
- FLC N/A
- RCEL N/A
- Revenue Growth
- FLC N/A
- RCEL 38.32
- 52 Week Low
- FLC $12.62
- RCEL $3.60
- 52 Week High
- FLC $15.45
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- FLC 76.91
- RCEL 34.84
- Support Level
- FLC $17.15
- RCEL $4.16
- Resistance Level
- FLC $17.25
- RCEL $4.43
- Average True Range (ATR)
- FLC 0.09
- RCEL 0.27
- MACD
- FLC 0.02
- RCEL -0.04
- Stochastic Oscillator
- FLC 97.57
- RCEL 5.51
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.